RxDoctor Payments Data

Garth Wilbanks, MD

Ophthalmology · Bangor, MENPI 1265420640

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.1% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 48.6% of the total. Reporting peaked in 2024 at $464 and has fallen 70.0% since, to $139 in 2025.

$1,337in general payments, 2019–2025

Across 60 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$650
  • Aerie Pharmaceuticals, Inc.$165
  • AbbVie$109
  • Amgen$80
  • Novartis$56
  • ANI Pharmaceuticals, Inc.$52
  • plus $225 from 7 others

What the payments were for

  • Food & beverage$1,21791%
  • Education$1007%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,337 in reported general payments places this provider in the 75th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$171,241
Medicare patients
362
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate383$19,704
RestasisCyclosporine15$19,648
RhopressaNetarsudil Mesylate25$11,937
RocklatanNetarsudil Mesylat/Latanoprost19$11,713
Methazolamide36$11,641
LumiganBimatoprost14$9,061
MoxifloxacinMoxifloxacin Hcl329$7,692
Fluorometholone82$7,118
Timolol Maleate261$6,582
SimbrinzaBrinzolamide/Brimonidine Tart16$5,516
Travoprost40$4,358
Latanoprost254$3,246
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat137$2,711
Famciclovir11$2,407
Brimonidine Tartrate156$2,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$109$28,70929 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$165$23,65144 claims
AlconSimbrinza$41$5,51616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →